Similar articles

• Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.

  Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Athyros VG, et al. World J Gastroenterol. 2015 Jun 14;21(22):6820-34. doi: 10.3748/wjg.v21.i22.6820. World J Gastroenterol. 2015. PMID: 26078558 Free PMC article. Review.
• A Critical Approach of Guideline Therapeutic Recommendations for NAFLD.

  Djordjevic DB, Zdravkovic M, Nagorni A, Manolis A, Tsioufis C, Lovic D. Djordjevic DB, et al. Curr Vasc Pharmacol. 2018;16(3):228-238. doi: 10.2174/1570161115666170621080228. Curr Vasc Pharmacol. 2018. PMID: 28676026 Review.
• Modern approach to the clinical management of non-alcoholic fatty liver disease.

  Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Del Ben M, et al. World J Gastroenterol. 2014 Jul 14;20(26):8341-50. doi: 10.3748/wjg.v20.i26.8341. World J Gastroenterol. 2014. PMID: 25024593 Free PMC article. Review.
• The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?

  Papademetriou M, Athyros VG, Geladari E, Doumas M, Tsioufis C, Papademetriou V. Papademetriou M, et al. Curr Vasc Pharmacol. 2018;16(3):254-268. doi: 10.2174/1570161115666170621081638. Curr Vasc Pharmacol. 2018. PMID: 28676027 Review.
• What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?

  Doumas M, Imprialos K, Stavropoulos K, Athyros VG. Doumas M, et al. Curr Vasc Pharmacol. 2019;17(5):425-428. doi: 10.2174/157016111705190703102816. Curr Vasc Pharmacol. 2019. PMID: 31418344 Review.